Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the companyâs transformative, high precision ophthalmic delivery platform. Eyenoviaâs pipeline is currently focused on the development of four programs including myopia (nearsightedness) progression, glaucoma and other eye diseases. Source
No articles found.
Novelion Therapeutics Inc. (âNovelion"), headquartered in Vancouver, British Col...
Novelion Therapeutics Inc. (âNovelion"), head...
At Insmed we are on a mission to transform the lives of patients battling serious ...
At Insmed we are on a mission to transform the ...
ImmuCell Corporationâs (Nasdaq: ICCC) purpose is to create scientifically-proven...
ImmuCell Corporationâs (Nasdaq: ICCC) purpose...
Voyager Therapeutics is developing life-changing gene therapies for fatal and debi...
Voyager Therapeutics is developing life-changin...
Bayer is a global enterprise with core competencies in the life science fields of ...
Bayer is a global enterprise with core competen...
Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a pharmaceutical company...
Alimera Sciences (NASDAQ: ALIM), founded in Jun...
Join the National Investor Network and get the latest information with your interests in mind.